About Innodx
COMPANY PROFILE
New Milestones
Change, is for continuous innovation.
Xiamen Innodx was founded in August, 2013, with a registered capital of 200 million yuan.
It is a member of Yangshengtang Group.
It is the wholly-owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., and a high technology enterprise dedicating in chemilumine - scence immunoassay IVD reagent research and development, manufacturing, and sales.
200+
Product registration certificate
100+
Luminous research project
60+
CE certified products
98%
Self-developed and self-produced raw materials for main projects
94%
94% Coverage rate of sold products in all provinces
COMPANY CULTURE
Enterprise Values
Innovation, excellence, hard work, win-win and responsibility
Technique Support
In “National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)” co-founded by Yangshengtang and Xiamen University, it replies on its strong research and development, and establishes a reliable Acridinium Ester Fully Automated Chemiluminescence Immunoassay (CLIA) platform.
Technical Strength
It undertakes national 863 Plan, National Infectious Diseases Major Projects, the 12th Five-Year Plan and the 13th Five-Year Supporting Plan of Ministry of Science and Technology, and many provincial and municipal scientific research projects. It rapidly transforms scientific research achievements, and fast realizes the industrialization development.
Group Strucure
COMPANY HISTORY
2010
Initiated tubular Chemiluminescence Immunoassay (CLIA) platform.
2011
Finished tubular Chemiluminescence Immunoassay (CLIA) platform and self-developed Acridinium Ester Substrate System;
Undertook the 12th Five-Year 863 project.
2012
Initiated 90 kinds of reagent research and development.
2013
Established Wantai Innodx.
2014
Entered the stage of registration and application of chemiluminescence products.
2015
Came into the market with first product “Diagnostic Kit for Alpha-fetoprotein (Chemiluminescent Microparticle Immunoassay)”;
Established and put into production of new plant.
2016
Came into the market with 60 kinds of chemiluminescence products regarding to infectious diseases, tumor markers, and cardiac markers.
2017
Came into the market with star product “Diagnostic Kit for Specific Cellular Immune Response to Mycobacterium tubeiculosis”.
2018
Developed first Double Antigen Sandwich Method “Hepatitis B core antibody quantitative detection reagent” in global and entered the Innovative Medical Device Product List (2018); at the same time this index was taken into 2018 Canadian chronic hepatitis B Management Handbook.
2020
In March, first Double Antigen Sandwich Method “Novel coronavirus total antibody detection reagent” in global was approved and came into the market.
— 
COMPANY HONORS
TypeYearsTitle
  • Award 2020Fujian New Research and Development Organization
  • Award 2020TUV ENISO 13485：2016 System Certification
  • Patent 2020Micro-fluidic chip control equipment, micro-fluidic control system, and micro-fluidic chip
  • Patent 2020Nucleic acid extraction device and nucleic acid extraction system
  • Patent 2020Chip clamp device and nucleic acid detection system
  • Patent 2020Micro-fluidic chip based fluorescence detection device and micro-fluidic chip detection system
  • Patent 2020Micro-fluidic chip puncture device and micro-fluidic chip detection system
  • Patent 2020Micro-fluidic chip module and micro-fluidic chip detection system
  • Patent 2020a kind of nucleic acid amplification reaction tube, reaction device and reagent (multiple countries) that can control fluid circulation path
  • Award 20192019 annual Big taxpayer
  • Award 2019Medical Device Institution Membership certificate
  • Award 2019New high-tech enterprise certificate
  • Award 2018Xiamen ‘Special, Fine, New’ small and micro enterprise
  • Patent 2018Micro-fluidic chip and biochemistry detection device
  • Patent 2018Micro-fluidic chip
  • Patent 2018Reagent storing modular, assembly of it and connected vessel, and micro-fluidic chip
  • Patent 2018Connected vessel, assembly of it with reagent modular, and micro-fluidic chip
  • Patent 2018Reaction chamber modular and micro-fluidic chip
  • Patent 2018Fluid guide value used for micro-fluidic chip and micro-fluidic chip
  • Patent 2018Method of extracting plasma from whole blood sample,blood filter, and micro-fluidic chip
  • Patent 2018Micro-fluidic chip, micro-fluidic system, and operating method
  • Award 2017Xiamen Scientific Little Giant Leading enterprise
  • Award 2017Infection series immune diagnosis reagent R&D and application, Xiamen Scientific and technological progress second award
  • Award 2016Excellent award of 5th China innovation venture contest (Xiamen area) and 2nd Egret Star innovation contest
  • Award 2016Finalist of 5th innovation venture contest
  • Patent 2016a kind of nucleic acid amplification reaction tube, reaction device and reagent (multiple countries) that can control fluid circulation path
  • Patent 2015Pratical and new type patent of a kind of magnetic seperation device
  • Patent 2015Hand-foot-and-mouth disease series immune diagnosis reagent R&D and application,Xiamen Scientific and technological progress second award
  • Award 2014Hand-foot-and-mouth disease series immune diagnosis reagent R&D and application,Xiamen Scientific and technological progress second award
  • Patent 2014Invention patent of a kind of acridinium ester enhanced chemiluminescence system
  • Award 2013Membership enterprise of 1st General Session of Fujian Medical Device Institution
  • Patent 2012Invention patent of Anti-HBC quantitative detection method and its usage on monitoring chronic hepatitis B patients' disease progression and predicting the treatment result
  • Patent 2011Invention patent of neutralizing epitope polypeptide of Enterovirus 71 and its usage
About Us|Product Center|News| Members |Join Us|Contact Us
Copyright  2021  XIAMEN INNODX BIOTECHNOLOGY CO., LTD.  ALL Rights Reserved. ICP Number: 16001770-1
WeChat